None listed
Conditions
Interventions
Dietary Supplement : • Chitooligosaccharide(GO2KA1) group: twice a day, 2 capsules once, after breakfast and dinner, for 12 weeks{1,600 mg/day, 1,200 mg/day for Chitooligosaccharide(GO2KA1)}
• Placebo
Sponsors
Wonkwang University. Iksan Korean Medicine Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 25 = BMI = 34.9 kg/m2 or 25%(male), 30%(female) =body fat percentage 2) Participants who have fully understood information provided about the study, voluntarily decided to participate, and agreed to comply with precautions
Exclusion criteria
Exclusion criteria: 1) Participants who have had a weight change of 10% of more within the 3 months prior to the screening examination. 2) Participants with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 3) Fasteners 4) Participants with a history of antipsychotic medication use within 3 months prior to the screening examination. 5) Participants who have participated in other interventional clinical trials within 3 months prior to the screening examination, or plan to participate in other interventional clinical trials. 6) Participants who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fat mass by DEXA(Dual-energy X-ray absorptiometry);Percent Body Fat by DEXA(Dual-energy X-ray absorptiometry) | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;Body Mass Index(BMI) | — |
Countries
Korea, Republic of
Contacts
Public ContactJeonghan Lee
Wonkwang University. Iksan Korean Medicine Hospital
Outcome results
None listed